Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.45 |
| ▸ | BCHE | P06276 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10243075 | 0.84 | CNR2 (0.43) | HTR6BCHEKDM4ESLC7A5MEN1 | |
| SCHEMBL10243252 | 0.79 | CNR2 (0.42) | KDM4ETLR7SLC7A5MEN1KMT2A | |
| SCHEMBL12028680 | 0.72 | SLC7A5 (0.55) | KDM4ETLR7SLC7A5MEN1KMT2A | |
| SCHEMBL10243056 | 0.72 | DRD4 (0.60) | KDM4ESLC7A5MEN1KMT2A | |
| SCHEMBL10243088 | 0.71 | POLB (0.53) | KDM4ENPC1MAPTTLR7MEN1 | |
| SCHEMBL10243264 | 0.71 | CNR2 (0.42) | KDM4EHTTMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL334788 | 0.71 | HTR1B (0.43) | HTR6KDM4EMAPT | |
| SCHEMBL335615 | 0.71 | MAPK14 (0.51) | NPC1MAPTHTTMEN1KMT2A | |
| SCHEMBL12028729 | 0.69 | SLC7A5 (0.56) | KDM4EMAPTTLR7SLC7A5MEN1 | |
| SCHEMBL5726879 | 0.69 | S1PR2 (0.47) | BCHEKDM4EMAPTTLR7SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | HTR6 3411/4885BCHE 1393/4885KDM4E 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.